[go: up one dir, main page]

WO2012131069A1 - Acides gras à chaîne courte et leurs dérivés à utiliser dans le traitement de troubles immunogènes - Google Patents

Acides gras à chaîne courte et leurs dérivés à utiliser dans le traitement de troubles immunogènes Download PDF

Info

Publication number
WO2012131069A1
WO2012131069A1 PCT/EP2012/055878 EP2012055878W WO2012131069A1 WO 2012131069 A1 WO2012131069 A1 WO 2012131069A1 EP 2012055878 W EP2012055878 W EP 2012055878W WO 2012131069 A1 WO2012131069 A1 WO 2012131069A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
virus
group
acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/055878
Other languages
English (en)
Inventor
Bettina ERNST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proponent Biotech GmbH
Original Assignee
Proponent Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proponent Biotech GmbH filed Critical Proponent Biotech GmbH
Publication of WO2012131069A1 publication Critical patent/WO2012131069A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • R 2 is -OR 3 ;
  • the compound of formula (I) is a compound according to the invention and as described herein in the various embodiments , wherein
  • R 2 is hydrogen
  • X is -0-
  • the compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
  • the compounds of this invention may also contain linkages (e. g., carbon- carbon bonds) wherein bond rotation is restricted about that particular linkage, e. g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis-trans and E/Z isomers are expressly included in the present invention.
  • the above compound or composition can also be used in a method for preparing a medicament.
  • R t represents hydrogen, carboxylic acid, C-rC 4 alkyl, hydroxy-C C alkyl wherein the alkyl group may be unsubstituted or substituted with one or more, same or different, substituents selected from the group consisting of hydroxyl, amino or carboxylic acid, preferably hydroxyl and/or carboxylic acid; and
  • R 2 is -OR 3 ;
  • R 2 is selected from the group consisting of hydrogen, hydroxyl or methyl
  • X is -0-
  • R represents d-C 4 alkyl, unsubstituted or substituted phenyl with one or more, same or different, substituents selected from the group consisting of nitro, halogen, amino, hydroxyl. cyano or methoxy, pheny!-Ci-C 4 alkyl wherein the phenyl group may be unsubstituted or substituted with one or more, same or different, substituents selected from the group consisting of halogen, nitro, amino, hydroxyl, cyano or methoxy, polyalkylene glycol;
  • the present invention relates to a SCFA compound of formula (1) according to the invention and as described herein in the various embodiments or to a pharmaceutically acceptable salt thereof, or to a composition comprising the SCFA compound of formula (I) according to the invention and as described herein in the various embodiments, or a pharmaceutically acceptable salt thereof, particularly in a therapeutically effective amount, optionally, together with a pharmaceutically acceptable carrier, for reducing the number of eosinophils in a subject treated with said compound and exposed to an immunogen, particularly in the airways of said subject, and thus for use in the treatment or prevention of an eosinophilic disease or disorder, or for amelioration of the condition of a subject suffering from such a disease or disorder.
  • Aryl means a monovalent, monocyclic, bicyclic or tricyclic, aromatic carbocyclic hydrocarbon radical, preferably a 6-14 member aromatic ring system.
  • Preferred aryl groups include, but are not limited to phenyl, naphthyl, phenanthrenyl, and anthracenyl, wherein the aryl group may be unsubstituted or substituted with one or more, same or different substituents selected from the group consisting of halogen; alkyl; alkyloxy, cyano, trifluoro, nitro, amino, hydroxyl.
  • Alkoxy means -O-alkyl, wherein alkyl has the meaning given above.
  • treatment means obtaining a desired pharmacological and/or physiological effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of partially or completely curing a disease and/or adverse effect attributed to the disease.
  • treatment covers any treatment of a disease in a subject and includes: (a) preventing a disease related to an undesired immune response from occurring in a subject which may be predisposed to the disease; (b) inhibiting the disease, i.e. arresting its development: or (c) relieving the disease, i.e. causing regression of the disease.
  • the immunogen may further be a polio antigen, herpes antigen (e.g., CMV, EBV, HSV antigens) mumps antigen, measles antigen, rubella antigen, diptheria toxin or other diptheria antigen, pertussis antigen, hepatitis (e.g., hepatitis A or hepatitis B) antigen (e.g., HBsAg, HBcAg, HBeAg), or any other vaccine immunogen known in the art.
  • herpes antigen e.g., CMV, EBV, HSV antigens
  • mumps antigen e.g., measles antigen, rubella antigen, diptheria toxin or other diptheria antigen, pertussis antigen
  • hepatitis e.g., hepatitis A or hepatitis B
  • antigen e.g., HBsAg, HBcAg,
  • the adjuvant according to the present invention represented by a compound of formula (I) as described herein in the various embodiments , can be used for a variety of purposes and administered in various way well known to those skilled in the art.
  • An exemplary disclosure of purposes and methods for administering an adjuvant is provided in WO 2006/085983.
  • the adjuvant according to the invention may be used generally in active or passive immunization for producing antibodies in vivo or in vitro, or in methods of producing antibodies against an immunogen for any other purpose, e.g. , for diagnostics or for use in histological techniques.
  • Figure 19 shows the results of propionate treatment of Feld-1 presensitized mice. Dendritic cells isolated from the lungs of mice previously treatment with sodium propionate are less effective at reactivating CD4+ T cells.
  • mice received either saline vehicle in drinking water or by injection.
  • Example 9 Results

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des acides gras à chaîne courte (SCFA) pour moduler une réponse immunitaire Th2 vers une réponse immunitaire Th1 pour la prévention et/ou l'amélioration d'infections virales et en tant qu'adjuvant pour favoriser l'efficacité de vaccins et/ou la prévention de maladies ou troubles allergiques, en particulier d'une maladie ou d'un trouble médié par des cytokines dérivées de lymphocytes T auxiliaires 2 (Th2), comprenant, sans y être limitées, IL-4, IL-5, IL-6, IL-8, IL-10 et IL-13, mais en particulier pour l'utilisation dans le traitement de maladies médiées par IL-4 et/ou IL-8 et/ou IgE et/ou maladies ou troubles des éosinophiles.
PCT/EP2012/055878 2011-03-31 2012-03-30 Acides gras à chaîne courte et leurs dérivés à utiliser dans le traitement de troubles immunogènes Ceased WO2012131069A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11160595 2011-03-31
EP11160558 2011-03-31
EP11160558.0 2011-03-31
EP11160595.2 2011-03-31

Publications (1)

Publication Number Publication Date
WO2012131069A1 true WO2012131069A1 (fr) 2012-10-04

Family

ID=45922694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055878 Ceased WO2012131069A1 (fr) 2011-03-31 2012-03-30 Acides gras à chaîne courte et leurs dérivés à utiliser dans le traitement de troubles immunogènes

Country Status (1)

Country Link
WO (1) WO2012131069A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014053592A1 (fr) * 2012-10-03 2014-04-10 Proponent Biotech Gmbh Esters d'acides gras à chaînes courtes pour l'utilisation dans le traitement de troubles immunogènes
WO2017137177A1 (fr) * 2016-01-04 2017-08-17 Replicon Health Oy Destiné à la prévention, au traitement et au soulagement de maladies et troubles infectieux
EP3207933A1 (fr) * 2016-02-17 2017-08-23 Proponent Biotech GmbH Utilisations de polyfructanes
EP3092008A4 (fr) * 2014-01-10 2017-09-06 The Regents of The University of California Probiotique pour la peau
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
CN109152753A (zh) * 2016-05-17 2019-01-04 拥护者生物技术有限公司 用于治疗/预防皮肤病的羧酸
US10196616B2 (en) * 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CN110475551A (zh) * 2017-01-27 2019-11-19 英联邦高等教育系统天普大学 使用短链脂肪酸治疗和预防疾病和障碍
EP3573612A4 (fr) * 2017-01-27 2020-11-18 Temple University Of The Commonwealth System Of Higher Education Utilisation d'acides gras à chaîne courte pour le traitement et la prévention de maladies et de troubles
WO2021003543A1 (fr) * 2019-07-08 2021-01-14 Universidade Estadual De Campinas Composés immunomodulateurs et/ou leurs sels pharmaceutiquement acceptables, composition pharmaceutique comprenant des composés immunomodulateurs et utilisation de composés immunomodulateurs dans la préparation d'une composition pharmaceutique pour le traitement de maladies virales
WO2021087072A1 (fr) * 2019-10-29 2021-05-06 Mohapatra Shyam S Compositions et procédés de prévention et de traitement de l'infection par le virus respiratoire syncytial
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
WO2022031787A1 (fr) * 2020-08-04 2022-02-10 Temple University-Of The Commonwealth System Of Higher Education Procédés et compositions pour traiter le syndrome de libération des cytokines
WO2022096637A1 (fr) 2020-11-05 2022-05-12 Aarhus Universitet Esters corporels de lactate/cétone
WO2023213874A1 (fr) 2022-05-04 2023-11-09 Aarhus Universitet Esters de lactate et de corps cétoniques combinés pour une utilisation médicale et nutritionnelle
US11963938B2 (en) 2015-01-23 2024-04-23 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
WO2025257398A1 (fr) * 2024-06-14 2025-12-18 Universite De Tours Acides dicarboxyliques et esters associés destinés à être utilisés dans le traitement d'une infection pulmonaire virale

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
WO2006085983A2 (fr) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Adjuvants viraux
JP2008195713A (ja) * 2007-01-19 2008-08-28 Shunkosha:Kk 免疫調節剤
EP2030616A1 (fr) * 2007-08-31 2009-03-04 Asan Laboratories Company (Cayman) Limited Dérivés d'acides gras à courte chaîne pour améliorer le prurit
WO2012022947A1 (fr) 2010-08-17 2012-02-23 Cmp Therapeutics Limited Compositions nutritionnelles comprenant des microparticules de chitine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) * 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
WO2006085983A2 (fr) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Adjuvants viraux
JP2008195713A (ja) * 2007-01-19 2008-08-28 Shunkosha:Kk 免疫調節剤
EP2030616A1 (fr) * 2007-08-31 2009-03-04 Asan Laboratories Company (Cayman) Limited Dérivés d'acides gras à courte chaîne pour améliorer le prurit
WO2012022947A1 (fr) 2010-08-17 2012-02-23 Cmp Therapeutics Limited Compositions nutritionnelles comprenant des microparticules de chitine

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BRUCE ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 59, no. 6, 1977, pages 449 - 59
CAVAGLIERI CLAUDIA R ET AL: "Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes.", LIFE SCIENCES, vol. 73, no. 13, 15 August 2003 (2003-08-15), pages 1683 - 1690, XP007919115, ISSN: 0024-3205 *
FUKUDA S ET AL: "Immunomodulator e.g. for treating allergosis, autoimmune disease and oral infection disease comprises acetic acid and/or propionic acid as active ingredients", WPI / THOMSON,, vol. 2008, no. 79, 28 August 2008 (2008-08-28), XP002651607 *
FURUHJELM CATRIN ET AL: "Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal [omega]-3 fatty acid supplementation during pregnancy and lactation.", PEDIATRIC RESEARCH MAR 2011 LNKD- PUBMED:21099447, vol. 69, no. 3, 1 March 2011 (2011-03-01), pages 259 - 264, XP007919116, ISSN: 1530-0447 *
MARSH; FREIDHOFF, ALBE, 1992, Retrieved from the Internet <URL:http://www.allergen.org/List.htm>
POLLART ET AL., J. ALLERGY CLIN. LMMUNOL., vol. 83, no. 5, 1989, pages 875 - 82
ROSENBERG ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 71, no. 3, 1983, pages 302 - 10
ROSENBERG, ANN. REV. MED., vol. 47, 1996, pages 481 - 491
SHERRY C L ET AL: "Sickness behavior induced by endotoxin can be mitigated by the dietary soluble fiber, pectin, through up-regulation of IL-4 and Th2 polarization", BRAIN, BEHAVIOR AND IMMUNITY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 24, no. 4, 1 May 2010 (2010-05-01), pages 631 - 640, XP027000812, ISSN: 0889-1591, [retrieved on 20100206] *
VAN ELDEN, L. J.; M. NIJHUIS; P. SCHIPPER; R. SCHUURMAN; A. M. VAN LOON: "Simultaneous detection of influenza viruses A and B using real-time quantitative PCR", J. CLIN. MICROBIOL., vol. 39, 2001, pages 196 - 200, XP002604453, DOI: doi:10.1128/JCM.39.1.196-200.2001
ZHANG Z ET AL: "Valproic acid attenuates inflammation in experimental autoimmune neuritis", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 65, no. 24, 27 October 2008 (2008-10-27), pages 4055 - 4065, XP019652181, ISSN: 1420-9071, DOI: DOI:10.1007/S00018-008-8521-4 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014053592A1 (fr) * 2012-10-03 2014-04-10 Proponent Biotech Gmbh Esters d'acides gras à chaînes courtes pour l'utilisation dans le traitement de troubles immunogènes
US9415033B2 (en) 2012-10-03 2016-08-16 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders
US9884032B2 (en) 2012-10-03 2018-02-06 Proponent Biotech Gmbh Esters of short chains fatty acids for use in the treatment of immunogenic disorders
EP2903608B1 (fr) * 2012-10-03 2019-08-28 Proponent Biotech GmbH Composition pharmaceutique comprenant de l'acide propionique pour son utilisation dans le traitement d'infections virales
EP3092008A4 (fr) * 2014-01-10 2017-09-06 The Regents of The University of California Probiotique pour la peau
US11590092B2 (en) 2014-01-10 2023-02-28 The Regents Of The University Of California Skin probiotic
EP3903824A1 (fr) * 2014-01-10 2021-11-03 The Regents of The University of California Probiotique pour la peau
US11963938B2 (en) 2015-01-23 2024-04-23 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
WO2017137177A1 (fr) * 2016-01-04 2017-08-17 Replicon Health Oy Destiné à la prévention, au traitement et au soulagement de maladies et troubles infectieux
EP3207933A1 (fr) * 2016-02-17 2017-08-23 Proponent Biotech GmbH Utilisations de polyfructanes
CN109152753A (zh) * 2016-05-17 2019-01-04 拥护者生物技术有限公司 用于治疗/预防皮肤病的羧酸
EP3573612A4 (fr) * 2017-01-27 2020-11-18 Temple University Of The Commonwealth System Of Higher Education Utilisation d'acides gras à chaîne courte pour le traitement et la prévention de maladies et de troubles
JP7161731B2 (ja) 2017-01-27 2022-10-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
JP7688360B2 (ja) 2017-01-27 2025-06-04 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
JP2020505471A (ja) * 2017-01-27 2020-02-20 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
US11759442B2 (en) 2017-01-27 2023-09-19 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
CN110475551A (zh) * 2017-01-27 2019-11-19 英联邦高等教育系统天普大学 使用短链脂肪酸治疗和预防疾病和障碍
JP2022179617A (ja) * 2017-01-27 2022-12-02 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
US10196616B2 (en) * 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
WO2021003543A1 (fr) * 2019-07-08 2021-01-14 Universidade Estadual De Campinas Composés immunomodulateurs et/ou leurs sels pharmaceutiquement acceptables, composition pharmaceutique comprenant des composés immunomodulateurs et utilisation de composés immunomodulateurs dans la préparation d'une composition pharmaceutique pour le traitement de maladies virales
WO2021087072A1 (fr) * 2019-10-29 2021-05-06 Mohapatra Shyam S Compositions et procédés de prévention et de traitement de l'infection par le virus respiratoire syncytial
WO2022031787A1 (fr) * 2020-08-04 2022-02-10 Temple University-Of The Commonwealth System Of Higher Education Procédés et compositions pour traiter le syndrome de libération des cytokines
WO2022096637A1 (fr) 2020-11-05 2022-05-12 Aarhus Universitet Esters corporels de lactate/cétone
WO2023213874A1 (fr) 2022-05-04 2023-11-09 Aarhus Universitet Esters de lactate et de corps cétoniques combinés pour une utilisation médicale et nutritionnelle
WO2025257398A1 (fr) * 2024-06-14 2025-12-18 Universite De Tours Acides dicarboxyliques et esters associés destinés à être utilisés dans le traitement d'une infection pulmonaire virale

Similar Documents

Publication Publication Date Title
WO2012131069A1 (fr) Acides gras à chaîne courte et leurs dérivés à utiliser dans le traitement de troubles immunogènes
US9884032B2 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
CN107746832A (zh) 一株高滴度的柯萨奇病毒a10驯化株及其应用
KR20100126390A (ko) 톨-유사 수용체 3의 선택적인 작용제
CN108025055B (zh) 多价肠道病毒疫苗组合物及其相关用途
JP7271433B2 (ja) 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用
WO2017125417A1 (fr) Tofacitinib comme immunomodulateur de vaccination
CN103695327B (zh) 一种口服重组酵母及其介导的靶向肠道DC呈递shRNA的应用
CN110452886B (zh) 一种柯萨奇cva4病毒株及其应用
CN110573179B (zh) 包含弱毒化的肺炎链球菌菌株的药剂学组合物及其用途
CN101085347B (zh) 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗
JP4024454B2 (ja) ＩｇＥ抗体産生低減剤およびアレルギー体質改善剤
CN102813920A (zh) 一种疫苗佐剂
CN112279912A (zh) 新型冠状病毒禽蛋抗体SARS-CoV-2-IgY制剂及其制备方法与应用
HK1210058B (en) Pharmaceutical composition comprising propionic acid for use in the treatment of viral infections
CN117042776A (zh) 疫苗佐剂
KR20250025356A (ko) 의료 적용 및 면역요법을 위한 4차 면역조절 나노입자의 방법 및 조성물
JP2009067679A (ja) 抗ヒスタミン作用を有する医薬
WO2023105247A1 (fr) Méthodes et compositions pour potentialiser la réponse immunitaire à l&#39;aide d&#39;inhibiteurs de la lysine désacétylase
CN100388953C (zh) 口服疫苗的复合黏膜免疫佐剂
CN103965288B (zh) 登革病毒特异性hla-a*2402限制性表位肽及应用
CN120302980A (zh) 免疫疗法组合物和使用方法
JP2025520698A (ja) 自己免疫疾患および炎症性疾患のための処置レジメン
CN117402798A (zh) 一种防治结核病的重组卡介苗药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12711410

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12711410

Country of ref document: EP

Kind code of ref document: A1